Biofrontera publishes report on the third quarter of 2014

Biofrontera AG / Biofrontera publishes report on the third quarter of 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Significant progress in business operations: excellent results in the phase 3 clinical study on the broad area therapy of actinic keratosis and completion of the safety studies required by the FDA

Patient recruitment for phase 3 study on basal cell carcinoma is in progress in Germany and the United Kingdom

Growth in sales of 31% in Germany compared to the nine-month period of the previous year

Other international sales remain slow ahead of the planned basal cell carcinoma trial

Leverkusen, 13 November 2014 - Today, Biofrontera AG (FSE/AIM: B8F), the biopharmaceutical company focusing on skin cancer, presents the company results for the first nine months of 2014. The quarterly report now published on the company's website (at http://biofrontera.com/en/) goes into detail in particular on the clinical development activities surrounding Biofrontera's skin cancer drug, Ameluz^®, and the preparations for the approval process in the US. In addition, the report covers national and international sales activities.

Development of the key financial figures in the first nine months of 2014

In the third quarter of the 2014 financial year, Biofrontera achieved a significant increase in revenue of 61% compared to the same period of the previous year. In Germany, where Biofrontera manages sales activities itself, sales grew by 54% compared to the same quarter of the previous year. The first nine months of the year resulted in revenue of EUR 1,992 thousand. While this was 7% higher overall than in the period for the previous year, sales in Germany increased significantly by 31% to EUR 1,399 thousand, which exceeded the revenue growth target for Germany. In contrast to this, the development in revenue outside Germany was still slow; in the first nine months, revenue from sales to foreign licensing partners fell from EUR 798 thousand in the first nine months of the previous year to EUR 523 thousand. Although revenue increased sales in the individual countries, the majority of these sales were fulfilled from existing inventory previously purchased by Biofrontera's local distribution partners. At this stage, it remains challenging to position Ameluz^@ in hospitals while the medicine is only approved for the treatment of actinic keratosis but not for the treatment of basal cell carcinoma. Consequently, we are expecting sales to increase as approval is extended for the treatment of basal cell carcinoma and the phase 3 clinical study required for this is under way.